IBD Unit, Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.
European Federation of Crohn's and Colitis Association, Brussels, Belgium.
J Crohns Colitis. 2019 Feb 1;13(2):259-266. doi: 10.1093/ecco-jcc/jjy150.
The increasing prevalence of inflammatory bowel disease and the high costs associated with biologic therapies suggest that biologics with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of biosimilars for many indications, including inflammatory bowel disease, patients may be concerned about the safety and efficacy of these agents. The updated Nurses-European Crohn's and Colitis Organisation statements, published in March 2018, recommend that inflammatory bowel disease nurses facilitate patient choice of biologic or biosimilar therapy. Nurses are pivotal in managing the challenges associated with patients transitioning to biosimilars. However, there is limited information available on how inflammatory bowel disease nurses can communicate the concept of biosimilars to patients and also on how best to support them before and during the switch from originators. This review article will focus on patients' concerns regarding biosimilars and describe considerations for nurses when supporting patients transitioning from originators to biosimilars. Through nurse-led patient education and the use of structured communication strategies, as well as investment in managed switching programmes, patients will become more confident and adherent to their biosimilar therapy, and this may lead to overall reductions in health-care expenditure for inflammatory bowel disease.
炎症性肠病的发病率不断上升，生物疗法相关费用高昂，这表明在制定炎症性肠病治疗方案时，应考虑使用成本较低但疗效和安全性不打折扣的生物制剂。生物类似药提供了一种更具成本效益的选择，尽管欧洲药品管理局已批准将生物类似药用于许多适应症，包括炎症性肠病，但患者可能会担心这些药物的安全性和疗效。2018 年 3 月发布的更新版《欧洲克罗恩病和结肠炎组织护士声明》建议，炎症性肠病护士应促进患者选择生物制剂或生物类似药治疗。护士在管理与患者转为生物类似药相关的挑战方面发挥着关键作用。然而，关于炎症性肠病护士如何向患者传达生物类似药的概念，以及在从原研药转为生物类似药之前和期间如何最好地支持他们，相关信息有限。本文将重点关注患者对生物类似药的担忧，并描述护士在支持患者从原研药转为生物类似药时需要考虑的问题。通过护士主导的患者教育和使用结构化沟通策略，以及对管理性转换计划的投资，患者对生物类似药治疗的信心和依从性将会提高，这可能会降低炎症性肠病的整体医疗费用。
